2008-09-05 22:35:01 -
- Cubist Pharma. (CBST) announces the following Webcast:
What: Investor Event: ACT 2-Raising the Curtain on Cubist's Pipeline
When: September 8, 2008 @ 4:30 PM Eastern
Where: www.investorcalendar.com/ClientPage.asp?ID=133534
How: Live over the Internet -- Simply log on to the web at the address above.
Contact: Michelle Vidoli, 781.860.8414, michelle.vidoli@cubist.com
If you are unable to participate during the live webcast, the call will be available for replay at
www.investorcalendar.com/ClientPage.asp?ID=133534 or
www.investorcalendar.com/
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. Cubist developed and commercialized CUBICIN(R) (daptomycin for injection), a Gram-positive first-in-class lipopeptide antibiotic. In the U.S. Cubist also promotes MERREM(R) I.V. (meropenem for injection), Astra Zeneca's established broad spectrum (carbapenem class) I.V. antibiotic. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials for the prevention of blood loss during cardiothoracic surgery, and pre-clinical programs that address unmet medical needs in Gram-positive infections, Gram-negative infections, CDAD (Clostridium difficile-associated diarrhea), and HCV (Hepatitis C infections). Cubist is headquartered in Lexington, MA. Additional information can be found at Cubist's web site at www.cubist.com.
Cubist Pharmaceuticals, Inc.
Michelle Vidoli, 781-860-8414
michelle.vidoli@cubist.com 
